 |
| |
 R&D Innovation & Strategies –Integrated Strategies To Over Come Pitfalls, Enhance Drug Discovery, Overcome Attrition & New Prediction Tools That Drive Clear Decision Making.
Focused Sirna Screens In Disease Based Assays - The Fast Track To A Target
Non-Invasive, Label-Free Assays - Getting the Most Out of your Targets and a Handle on Off-Target Effects
In Silico Innovation To Solve Drug Discovery – In-Silico Data, Data Mining, Predictive Modeling,
Exploring the impact & success rate of HTS Compound Library Screening.
Partnerships, Alliances & Outsourcing –Successful Partnerships, Managing Alliances, Balancing Conflicting Interests, Biotech Technology Platforms
Intergration of technologies & applications to bridge the gap between discovery, validation & development
How do you create intelligence from all this data, both structured and unstructured, across the entire value chain?
Streamline data processes and integration whilst improving early decision making and lowering attrition through the benefit of developing a dynamic workflows and an efficient infrastructure.
“An innovative approach”-lean/ 6-sigma efforts and organisational structures supporting lead optimisation."
Alternative cost effective screening methods and techniques to strengthen assay effectively. Bringing in-vitro screening for HTS, hit optimisation & lead optimisation together.
|
|
|
 |
|
|
|
|
|
|
|
|
|
| |
 |
Sid Topiol
Associate Director, Computational Chemistry
Lundbeck Research, USA.
I started as a quantum chemist working on methods to treat large systems. I worked with Jules Moskowitz at NYU, Mark Ratner at Northwestern University and John Pople (Nobe Laureate) at Carnegie-Mellon University . My first position was on the faculty of the Pharmacology Department at The Mount Sinai School of Medicine, where there was a focus on molecular pharmacology dealing with the CNS, particularly for GPCR targets, including histamine and serotonin receptors.
I then took an industry position at Berlex, which was mainly interested in cardiovascular drugs. I started a computational group there, working mostly on ligand-based drug design. A few years later I moved to Sandoz, which later became Novartis. Much of the emphasis of the work there was on targets where X-ray structures of the targets, or of close homologs, were available.
This allowed for the greatest impact on ongoing projects through the use of Structure Based Drug Design approaches. I recently took a position at Lundbeck Research , USA , which focuses on CNS therapeutics. |
|
|
|
|
|
 |
|
|
| |
 |
Dr. Magdalena Tary-Lehmann
Chief Scientific Officer
Cellular Technology Limited
Dr. Magdalena Tary-Lehmann is a Co-Founding Scientist and Chief Scientific Officer for Cellular Technology Limited. Dr. Tary-Lehmann received her M.D. in 1988 and her Ph.D. in Immunology in 1993, both from the University of Tübingen, Germany. Her postdoctoral training in Immunology was at the University of California, Los Angeles (UCLA), 1989-1993.
She subsequently moved in 1993 to Case Western Reserve University, and in 2003 was awarded tenure and appointed to Associate Professor in their Department of Pathology. In her current capacity as Chief Scientific Officer, she provides guidance and oversight for technical operations and for ensuring the scientific excellence of the company.
Over the past ten years, she has worked with both clients and regulatory agencies to develop and validate reference samples and controls for use in regulated immune monitoring assays. |
|
|
|
|
|
|
|
|
|
|
|
| |
 |
Jonathan Mason PhD FRSC
Head of Computational Chemistry, Heptares Therapeutics, UK
Chief Scientist (Predictive Technologies & Drug Design), Medicinal Chemistry, Lundbeck Research
Dr. Jonathan Mason currently has roles as Head of Computational Chemistry at Heptares Therapeutics Ltd (UK) and as a Chief Scientist at Lundbeck Research (Denmark). He is a global Pharma experienced leader and scientific expert for drug design technologies (computational medicinal chemistry / CADD, structural biology, in silico ADME/tox etc) and has previously led teams involving Computational Chemistry, Structural Biology, Medicinal Informatics and Knowledge Discovery at Pfizer in the UK (Executive Director MISD) and Bristol-Myers Squibb in the US (Director SB&M), following many years at Rhône-Poulenc Rorer (now Sanofi-Aventis) in the UK, France and US building and leading Computer-Assisted Drug Design teams. Dr. Mason started his career as a medicinal chemist, and has 30 years of pharmaceutical drug discovery experience. He has been a pioneer in the development and use of 3D pharmacophore fingerprint methods for both protein structure-based drug design (SBDD) and ligand-based similarity/diversity approaches, together with de novo design & target class approaches. More recently he has driven the use of biological fingerprints to tackle attrition-related problems including lead selection / differentiation |
|
|
|
|
|
|
|
|
| |
 |
Hans (Johann) Winkler, M.S., Ph.D.
Senior Director, Head Oncology Biomarker Research
Ortho Biotech Oncology Research & Development. Johnson&Johnson
Hans (Johann) Winkler is senior director at Ortho Biotech Oncology Research & Development leading Oncology Biomarker Discovery and Development globally. Hans originally joined the J&JPRD Drug Discovery team in Beerse in 2003 as the head of Functional Genomics, a newly created department combining genomic technologies and bioinformatics. Before joining J&JPRD, he was Director and Global Program Manager for Target Validation Technologies at AstraZeneca, plc in Manchester , UK , with responsibility for target validation technology assessment and acquisition across all disease areas globally.
He held positions of increasing responsibility at Zeneca, including team leader in Target Discovery, working mainly in the cardiovascular area, and senior group leader and associate director responsible for TI/TV activities and technology assessment and acquisition across several disease areas. Prior to this, he was a scientist and instructor at Harvard Medical School's Deaconess Hospital (now Beth Israel Deaconess Hospital) in Boston, where he worked on endothelial cell biology and immunobiology in a xenotransplantation context, after work as a scientist and group leader at the Vienna International Research Cooperation Center in Vienna (Novartis Research Institute) working on gene regulation in endothelial cells.
Hans was born in Austria , where he received his primary and secondary education. He studied Biochemistry at the University of Vienna after which he was awarded a Fulbright fellowship to attend graduate school in the U.S. where he obtained a Master's degree in Molecular Biology (working on Caenorrhabditis elegans) from the University of Houston in 1986. Hans then returned to Vienna to work on his PhD thesis. He completed his postdoctoral work at the Institute for Molecular Pathology.
Hans is co-author of some forty original, peer-reviewed publications and book chapters and inventor on two patents. |
|
|
|
|
|
|
|
|
